Simulations Plus Reports Preliminary Results for Third Fiscal Quarter
Company CEO to Present at New York City Investor Meeting and Webinar
Simulations Plus Announces Change In Acquisition Status
One Pharmaceutical Acquisition Declined, Others Under Investigation
Simulations Plus Appoints Michael Pelekis, PH.D., Director for Business Development
New Position To Focus On Acquisitions And Collaborations
Simulations Plus Wins Phase II, Small Business Innovation Research Grant
$525,000 Grant to Speed Commercialization of Advancements to Company’s Industry-Leading Molecular Property Prediction Software
Simulations Plus Reports Second Quarter FY2009 Financial Results
Continued Growth – Revenues Up 12.7%, Cash Up 20.2%
Simulations Plus Sets Date for Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
Conference Call to be on Wednesday, April 15, at 4:15 PM EDT
Simulations Plus Reports First Quarter FY2009 Financial Results
Company Sets New Record for First Quarter: Revenues up 7.5% and Earnings Up Over 28%
Simulations Plus Sets Date for First Quarter Fiscal Year 2008 Earnings Release and Conference Call
Conference Call to be on Thursday, January 15, at 4:15 PM EST
Simulations Plus Releases ClassPharmer™ Version 4.6
New Version Further Improves Powerful Data Mining and Drug Design Capabilities
Simulations Plus Reports FY2008 Financial Results
Earnings Up 17.7%, Shareholder Equity Up 29.4% Over Previous Fiscal Year
Simulations Plus Announces Share Repurchase Program
Up to $2.5 million over 12 months authorized by board of directors
Simulations Plus Signs Another Collaboration Agreement
Companies to Cooperate on Development of Advanced Ocular Delivery Simulation
U.S. FDA Licenses ADMET Predictor™ from Simulations Plus
Adds Property Prediction Software to Earlier GastroPlus(™) Licenses
U.S. National Institutes of Health Renews ClassPharmer Software Licenses
Chemical Genomics Center Renews Five Licenses
Simulations Plus and Roche Sign Multi-year Collaboration
Collaboration to Develop Drug-Drug Interaction Capability in GastroPlus™
Simulations Plus Subsidiary, Words+, Inc., Releases Major New Product
"Conversa(™)" System Offers 12-inch Touch Tablet With Superior Voice Quality And Volume